BioCentury | Aug 16, 2018
Distillery Therapeutics

Gastrointestinal

...the disease, systemic knockout of RAG2 or IL-6 decreased GI polyp size compared with normal RAG2...
...chimeric mAb against IL-6, to treat cancer. TARGET/MARKER/PATHWAY: Janus kinase-1 (JAK-1); JAK-2; interleukin-6 (IL-6); recombination activating gene 2 (RAG2...
...Jones, McGill University, Montreal, Quebec email: russell.jones@mcgill.ca; russell.jones@vai.org Sandi Wong McGill University Interleukin-6 (IL-6) Janus kinase-1 (JAK-1) Janus kinase-2 (JAK-2) Recombination activating gene 2 (RAG2) Gastrointestinal...
BioCentury | Jul 5, 2017
Clinical News

Yungjin begins Phase I of NAD+ modulator KL1333

Yungjin Pharmaceutical Co. Ltd. (KSE:003520) began a double-blind, placebo-controlled, dose-escalation, Korean Phase I trial to evaluate safety and pharmacokinetics of single doses of oral KL1333 in 60 healthy volunteers. The product is a nicotinamide adenine...
BioCentury | May 5, 2017
Company News

NeuroVive gains NAD+ modulator from Yungjin for mitochondrial disorders

Yungjin Pharmaceutical Co. Ltd. (KOSDAQ:003520) granted NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) exclusive, worldwide rights to develop and commercialize mitochondrial disorders candidate KL1333 outside of Korea and Japan, where Yungjin retains rights. NeuroVive will pay Yungjin...
BioCentury | Apr 7, 2017
Targets & Mechanisms

Mastering mTOR

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...
BioCentury | Mar 10, 2016
Distillery Therapeutics

Therapeutics: Recombination activating gene 2 (RAG2)

...form of severe combined immunodeficiency associated with mutations in recombination activating genes (RAGs). In a RAG2-mutant...
...in other diseases associated with chronic inflammation of the small intestine and colon. TARGET/MARKER/PATHWAY: Recombination activating gene 2 (RAG2...
BioCentury | Jun 29, 2015
Product Development

Insights in interception

Four months after launching an R&D group to predict and prevent progression to disease, Janssen Research & Development LLC has revealed the center's first research collaboration in Type I diabetes, named two new disease areas...
BioCentury | Jun 5, 2014
Distillery Techniques

Technology: Disease models

...Disease models Recombination activating gene 2 (RAG2) knockout pigs to model immunodeficiency and evaluate transplant-based therapies Pigs with RAG2...
...transplant-based therapies. In vitro, engineered transcription activator-like effector nucleases (TALENs) were used to knock out RAG2...
...used in a somatic cell nuclear transfer procedure to generate eight RAG2 knockout pigs. The RAG2...
BioCentury | Mar 6, 2014
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing to produce genetically modified monkeys Primate studies suggest CRISPR could be used to develop genetically modified...
BioCentury | Feb 17, 2014
Company News

Cellectis, Precision BioSciences deal

The companies will cross-license their respective technologies to settle infringement suits filed by both companies related to engineered I-CreI meganuclease technology. Precision declined to comment, and Cellectis could not be reached. The history includes many...
BioCentury | Sep 27, 2012
Distillery Techniques

Technology: Disease models

...that target the liver stage of human malarial strain Plasmodium falciparum. In the mice, recombination activating gene 2 (Rag2...
Items per page:
1 - 10 of 31